Teclistamab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Teclistamab. Educational only — not medical advice.
Labeled uses
TECVAYLI is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma in combination with daratumumab and hyaluronidase-fihj in patients who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent. as monotherapy, in patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.
Source: FDA labeling via NIH DailyMed (set 54e0f974…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.